Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay005 (Mufemilast) in Behçet's Disease
NCT06145893Phase 3Recruiting
- Sponsor
- Hemay Pharmaceutical Technology
- Start
- Nov 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mufemilast in Behçet's disease (BD) (3 arms), sponsored by Hemay Pharmaceutical Technology. Primary endpoint: Efficacy assessed by oral ulcers at 12 weeks. Started Nov 2023; status: recruiting.
02
Drugs
mufemilast
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT06145893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06145893.